Polymyalgia Rheumatica

Conclusions  The scarcity of randomized trials and the high level of heterogeneity of studies on PMR therapy do not allow firm conclusions to be drawn. However, PMR remission seems to be achieved with prednisone treatment at a dose of 15 mg/d in most patients, and reductions below 10 mg/d should preferably follow a tapering rate of less than 1 mg/mo. Methotrexate seems to exert glucocorticoid-sparing properties. (Source: Archives of Internal Medicine)
MedWorm: Polymyalgia Rheumatica

Related posts:

1. Systematic review: Treatment of polymyalgia rheumatica ch_client = "wildplus"; ch_width = 200; ch_height = 200; ch_type = "mpu"; ch_sid = "Polymyalgia 200x200"; ch_color_site_link = "#36727D"; ch_color_title...
2. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity Conclusions: 12.5 mg prednisone is a sufficient starting dose in of PMR patients. The main factor driving response to prednisone...
3. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity Conclusions: 12.5 mg prednisone is a sufficient starting dose in of PMR patients. The main factor driving response to prednisone...
4. Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica This study is concerned with an evaluation of the effects of glucocorticoids (GC) on adiponectin and leptin concentrations in patients...
5. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis Conclusion  We found overall valuable diagnostic performances for FDG PET against reference criteria. Standardized FDG uptake criteria are needed to optimize...